NewsNational

Actions

Blood pressure medicine Irbesartan has been recalled due to cancer-causing impurity

Posted: 1:24 PM, Jan 22, 2019
Updated: 2019-01-22 14:03:42-05
Blood pressure medicine Irbesartan has been recalled due to cancer-causing impurity

A drug company announced on Friday that eight lots of Irbesatan blood pressure medication have been recalled after testing showed the medication contained trace amounts of a cancer-causing material.

Specifically, one lot of Irbesartan tablets and seven lots of Irbesartan HCTZ tablets were recalled.

Prinstin Pharmaceuticals said the medication contained unacceptable levels of Nitrosodiethylamine -- or NDEA-- a likely carcinogen.

The ingredients were manufactured by Zheijiang Huahai Pharmaceuticals in China, a company which has been linked to several recalls of regularly-prescribed blood pressure drugs since July.

These are the lots that have been recalled, per the FDA:

RBESARTAN TABLETS 300MG 90CT43547-376-09331B1800902/20218/9/2018
IRBESARTAN/HCTZ
300MG/12.5MG 30CT TABLETS
43547-331-03327A1800103/20217/10/2018
IRBESARTAN/HCTZ
300MG/12.5MG 30 CT TABLETS
43547-331-03327A1800203/20217/10/2018
IRBESARTAN/HCTZ 300MG/12.5MG 90CT
TABLETS
43547-331-09327B1800803/20217/10/2018
IRBESARTAN/HCTZ 300MG/12.5MG 90CT
TABLETS
43547-331-09327B1800903/20217/10/2018
IRBESARTAN/HCTZ 150MG/12.5MG 30CT43547-330-03325D1800403/20217/10/2018
IRBESARTAN/HCTZ
150MG/12.5MG 90CT TABLETS
43547-330-09325B1800403/20218/24/2018
IRBESARTAN/HCTZ 150MG/12.5MG 30CT
TABLETS
43547-330-03325D1800503/20217/10/2018

RELATED: New year, new blood pressure medication recall: Drug tablets recalled over cancer concern

RELATED: Blood pressure drug recall expands again